Metformin doesn't suppress the aromatase expression breast cancer tissue of patients with concurrent type 2 diabetes

Voprosy Onkologii

Volumn 58, Issue 2, 2012, Pages 194-198

  Berstein, L M ^a   Turkevich, E A ^a   Boyarkina, M P ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; METFORMIN; PROGESTERONE RECEPTOR; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DIET; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

AGED; AROMATASE; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; METFORMIN; MIDDLE AGED; RECEPTORS, PROGESTERONE;

EID: 84864068418     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Allred D. C., Harvey J. M., Berando M., Clark G. M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis // Mod. Pathol. - 1998. - Vol. 11. - P. 155-168.
2. Barone B. B., Yeh H. C., Snyder C. F. et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis // JAMA. - 2008. - Vol. 300. - P. 2754-2764.
3. Berstein L. M., Boyarkina M. P., Tsyrlina E. V. et al. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin // Med. Oncol. - 2011. - Vol. 28. - P. 1260-1263.
4. Bodmer M., Meier C., Krähenbühl S. et al. Long-term metformin use is associated with decreased risk of breast cancer // Diabetes Care. - 2010. - Vol. 33. - P. 1304-1308.
5. Bowker S. L., Majumdar S. R., Veugelers P. et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin // Diabetes Care. - 2006. - Vol. 29. - P. 254-258.
6. Brown K. A., Hunger N. I., Docanto M. et al. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase // Breast Cancer Res. Treat. - 2010. - Vol. 123. - P. 591-596.
7. Burul-Bozkurt N., Pekiner C., Kelicen P. Diabetes alters aromatase enzyme levels in gonadal tissues of rats // Naunyn Schmiedebergs Arch. Pharmacol. - 2010. - Vol. 382. - P. 33-41.
8. Decensi A., Puntoni M., Goodwin P. et al. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis // Cancer Prev. Res. (Philad.). - 2010. - Vol. 3. - P. 1451-1461.
9. Dowling R.J.O., Goodwin P. J., Stambolic V. Understanding the benefit of metformin use in cancer treatment // BMC Medicine. - 2011. - Vol. 9. - P. 33.
10. Geisler J., Suzuki T., Helle H. et al. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status // J. Steroid. Biochem. Mol. Biol. - 2010. - Vol. 118. - P. 237-241.
11. Metformin triallists' collaboration, Stevens R., McLellan J. et al. Cancer and all-cause mortality: meta-analysis of randomized clinical trials of metformin // ADA Meeting. - 2011. - Abstr. 0950-P.
12. Nestler J. E. Regulation of the aromatase activity of human placental cytotrophoblasts by insulin, insulin-like growth factor-I, and -II // J. Steroid Biochem. Mol. Biol. - 1993. - Vol. 44. - P. 449-457.
13. Prabhu A., Xu Q., Manigrasso M. B. et al. Expression of aromatase, androgen and estrogen receptors in peripheral target tissues in diabetes // Steroids. - 2010. Vol. 75. - P. 779-787.
14. Rice S., Pellatt L., Ramanathan K. et al. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway // Endocrinology. - 2009. Vol. 150. - P. 4794-4801.
15. Santen R. J., Brodie H., Simpson E. R. et al. History of Aromatase: Saga of an Important Biologic Mediator and Therapeutic Target // Endocrin. Rev. - 2009. - Vol. 30. - P. 343-375.
16. Sasano H., Anderson T. J., Silverberg S. G. et al. The validation of new aromatase monoclonal antibodies for immunohistochemistry -a correlation with biochemical activities in 46 cases of breast cancer // J. Steroid Biochem. Mol. Biol. - 2005. - Vol. 95. - P. 35-39.
17. Sasano H., Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies // Endocrin. Rev. - 1998. - Vol. 19. - P. 593-607.
18. Segal E. D., Yasmeen A., Beauchamp M. C. et al. Relevance of the OCT1 transporter to the antineo-plastic effect of biguanides // Biochem. Biophys. Res. Commun. - 2011 Oct/ 2. [Epub ahead of print].
19. Silva J. M., Price C. A. Insulin and IGF-I are necessary for FSH-induced cytochrome P450 aromatase but not cytochrome P450 side-chain cleavage gene expression in oestrogenic bovine granulosa cells in vitro // J. Endocrinol. - 2002. - Vol. 174. - P. 499-507.
20. Stamataki K. E., Spina J., Rangou D. B. et al. Ovarian function in women with non-insulin dependent diabetes mellitus // Clin. Endocrinol. (Oxf.). - 1996. - Vol. 45. - P. 615-621.
21. Takemura Y., Osuga Y., Yoshino O. et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92. - P. 3213-3218.
22. Uzelac P. S., Li X., Lin J. et al. Dysregulation of leptin and testosterone production and their receptor expression in the human placenta with gestational diabetes mellitus // Placenta. - 2010. - Vol. 31. - P. 581-588.
23. Wild S. H. Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to dis-entangle the web of associations // Diabetologia. - 2011. - Vol. 54. - P. 1589-1592.
24. Vigneri P., Frasca F., Sciacca L. et al. Diabetes and cancer // Endocrin. Relat. Cancer. - 2009. - Vol. 16. - P. 1103-1123.